
News|Articles|June 2, 2019
- Pharmaceutical Technology-06-02-2019
- Volume 43
- Issue 6
Supply Chain Risk and Security Maturity Evolution
Discussing supply chain risk and security as a business led journey, Roddy Martin, chief digital strategist at TraceLink, explains the five stages of its evolution.
Advertisement
Discussing supply chain risk and security as a business led journey, Roddy Martin, chief digital strategist at TraceLink, explains the five stages of its evolution to Pharmaceutical Technology:
- "Stage 1. Reacting to risk and security problems after the fact.
- Stage 2. Specialized security and risk management projects; for example, track and trace/serialization.
- Stage 3. Supply chain risk and security are a functional excellence capability; for example, risk and security requirements are codified into all work within functions like manufacturing, procurement, logistics, and so on.
- Stage 4. Supply chain and risk are codified as core ‘this is how we work’ requirements in all horizontal, end-to-end, and cross-functional processes from the patient all the way back through the business into all elements of supply.
- Stage 5. Risk and security capabilities are embedded into and across the total ecosystem and network both internal and external to a company; the core capability is that product integrity, availability, and patient safety are regarded as a given. In stage 5, risk and security are both driven as value based capabilities rather than seen as a cost.”
Article Details
Pharmaceutical Technology
Vol. 43, No. 6
June 2019
Page: 45
Citation
When referring to this article, please cite it as F. Thomas, “Supply Chain Risk and Security Maturity Evolution,” Pharmaceutical Technology 43 (6) 2019.
Articles in this issue
over 7 years ago
Hovione Technology Develops Blister-Based Inhalerover 7 years ago
Enabling Technologies Advance Poorly Soluble Highly Potent APIsover 7 years ago
Pharma Facilities Still Have a Lot to Learnover 7 years ago
Filling the Early Intermediate Security Gapover 7 years ago
As Easy as ABC?over 7 years ago
Regulating Cannabis-Based Medicines in Europeover 7 years ago
On the Right Trackover 7 years ago
Looking Beyond the Solubility Horizonover 7 years ago
Enhancing Bioavailability with Hot-Melt ExtrusionAdvertisement
Related to this article

FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.

Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.

The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.

Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.

Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.

Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.

From AI validation to microstructure imaging, AAPS PharmSci 360 speakers pushed toward faster drug development backed by stronger evidence. Here are PharmTech's biggest takeaways.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
France Remains One of Europe’s Leading Biotech Funding Hubs
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5


